Table: GSK's Strengths and Challenges

Lots of Cash and Products...

Sales in 2000 totaled $25.6 billion, profits reached $5.6 billion, the annual R&D budget approached $4 billion. Now, GSK is the leading supplier of antibiotics, antivirals, and respiratory drugs.

...But Weak Spots

To come up quickly in cancer and cardiovascular drugs, where the pipeline is thin, GSK is likely to acquire biotech or pharmaceutical products--or players--in the U.S., Europe, and Japan.

Data: Evaluate PLC

Before it's here, it's on the Bloomberg Terminal.